Zenkuda and KSI-501 in wAMD: The ongoing Phase 3 DAYBREAK study is designed to evaluate immediacy, real-world durability and efficacy Topline data 3Q 2026 Noninferiority Zenkuda 6-month durability KSI-501 efficacy exploration Phase 3 DAYBREAK Zenkuda objective: Assess 6-month durability potential in wAMD KSI-501 objective: Explore efficacy potential of bispecific IL-6 and VEGF inhibition in wAMD AI-based tool precisely measures fluid in the eye to optimize treatment per patient • High-need patients: treats until dry, enables monthly dosing and detects disease reactivation earlier • Long-durability patients: allows patients without active disease to safely go to every 6-month dosing 32